ATE505481T1 - Fusionsproteine der tnf-superfamilie - Google Patents
Fusionsproteine der tnf-superfamilieInfo
- Publication number
- ATE505481T1 ATE505481T1 AT07801940T AT07801940T ATE505481T1 AT E505481 T1 ATE505481 T1 AT E505481T1 AT 07801940 T AT07801940 T AT 07801940T AT 07801940 T AT07801940 T AT 07801940T AT E505481 T1 ATE505481 T1 AT E505481T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- tnf superfamily
- present
- fusion protein
- tnfsf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06017891A EP1894940A1 (de) | 2006-08-28 | 2006-08-28 | TNF Superfamilie Fusionsproteine |
| PCT/EP2007/007517 WO2008025516A2 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505481T1 true ATE505481T1 (de) | 2011-04-15 |
Family
ID=37836940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07801940T ATE505481T1 (de) | 2006-08-28 | 2007-08-28 | Fusionsproteine der tnf-superfamilie |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8147843B2 (de) |
| EP (2) | EP1894940A1 (de) |
| JP (1) | JP5274464B2 (de) |
| AT (1) | ATE505481T1 (de) |
| AU (1) | AU2007291490A1 (de) |
| CA (2) | CA2661599C (de) |
| DE (1) | DE602007013920D1 (de) |
| WO (1) | WO2008025516A2 (de) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3321277B1 (de) | 2007-07-10 | 2019-09-18 | Apogenix AG | Collectin-fusionsproteine der tnf-superfamilie |
| EP2540740B1 (de) * | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimere TNF-Rezeptoren |
| WO2010006772A2 (en) * | 2008-07-14 | 2010-01-21 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| EP2310509B1 (de) | 2008-07-21 | 2015-01-21 | Apogenix GmbH | Tnfsf-einkettenmoleküle |
| JP5844158B2 (ja) | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| JP6373836B2 (ja) | 2012-07-26 | 2018-08-15 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 多量体融合タンパク質ワクチン及び免疫療法 |
| WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| NO2776305T3 (de) | 2014-04-23 | 2018-01-27 | ||
| BR102014031185A8 (pt) * | 2014-12-12 | 2021-05-04 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp | proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer |
| DK3247728T3 (da) | 2015-01-20 | 2020-07-13 | Igm Biosciences Inc | Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| EP3076179A1 (de) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnose und behandlung von minderwertigen glioma |
| CA2999116A1 (en) | 2015-09-23 | 2017-03-30 | Apogenix Ag | Anti-cd95l antibody |
| EP3374504B1 (de) * | 2015-11-09 | 2025-03-19 | CureVac SE | Optimierte nukleinsäuremoleküle |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US20200121719A1 (en) | 2017-01-06 | 2020-04-23 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| CA3062874A1 (en) | 2017-05-10 | 2018-11-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| US11819517B2 (en) | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| EP3664832B1 (de) * | 2017-08-11 | 2023-10-18 | The Board of Trustees of the University of Illinois | Verkürzte l-asparaginase-varianten vom meerschweinchen und verfahren zur verwendung |
| JP7557367B2 (ja) | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細針吸引及び小生検からのｔｉｌ拡大培養 |
| CA3083118A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| JP7565795B2 (ja) | 2017-12-15 | 2024-10-11 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法 |
| BR112020013848A2 (pt) | 2018-01-08 | 2020-12-01 | Iovance Biotherapeutics, Inc. | métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| CA3090795A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| SG11202009170UA (en) | 2018-03-29 | 2020-10-29 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN112368003A (zh) | 2018-04-27 | 2021-02-12 | 艾欧凡斯生物治疗公司 | 肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途 |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| MX2021002887A (es) | 2018-09-20 | 2021-06-04 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumores (tils) a partir de muestras de tumor crioconservadas. |
| JOP20210094A1 (ar) | 2018-11-05 | 2023-01-30 | Iovance Biotherapeutics Inc | عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي |
| BR112021008549A2 (pt) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor |
| WO2020096927A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| EP3877512A2 (de) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Selektion verbesserter tumorreaktiver t-zellen |
| EP3898949A1 (de) | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Verfahren zur expansion tumorinfiltrierender lymphozyten unter verwendung von manipulierten cytokin-rezeptorenpaaren und deren verwendungen |
| AU2020233284A1 (en) | 2019-03-01 | 2021-09-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| BR112021019328A2 (pt) | 2019-03-29 | 2021-11-30 | Myst Therapeutics Llc | Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados |
| US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| JP2022553389A (ja) | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
| CA3162703A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| AU2021226903A1 (en) | 2020-02-27 | 2022-10-20 | Turnstone Biologics Corp. | Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| US20230172987A1 (en) | 2020-05-04 | 2023-06-08 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| IL300632A (en) * | 2020-08-24 | 2023-04-01 | Sanofi Pasteur Inc | Vaccines against SARS-COV-2 infections |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| TW202241468A (zh) | 2020-12-11 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者 |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| EP4262827A1 (de) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Behandlung von krebs mit tumorinfiltrierenden lymphozyten |
| EP4288140A1 (de) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvante therapie für krebs |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| JP2024515189A (ja) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用 |
| EP4340850A1 (de) | 2021-05-17 | 2024-03-27 | Iovance Biotherapeutics, Inc. | Pd-1-geneditierte tumorinfiltrierende lymphozyten und verwendungen davon in der immuntherapie |
| US20240254193A1 (en) * | 2021-05-27 | 2024-08-01 | Bejing Anxinhuaide Biotech, Co., Ltd | A super-trail molecule comprising two trail trimers |
| WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
| CA3235824A1 (en) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| EP4430167A1 (de) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Verfahren zur expansionsbehandlung mit cd8-tumorinfiltrierenden lymphozyten |
| US20250101380A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| EP4507704A1 (de) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til-expansionsverfahren unter verwendung spezifischer zytokinkombinationen und/oder einer akti-behandlung |
| EP4565683A1 (de) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimäre kostimulatorische rezeptoren, chemokinrezeptoren und deren verwendung in zellulären immuntherapien |
| WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1365027A4 (de) * | 2000-05-26 | 2005-06-22 | Mochida Pharm Co Ltd | Mit fas-liganden fusioniertes protein |
-
2006
- 2006-08-28 EP EP06017891A patent/EP1894940A1/de not_active Withdrawn
-
2007
- 2007-08-28 DE DE602007013920T patent/DE602007013920D1/de active Active
- 2007-08-28 AT AT07801940T patent/ATE505481T1/de not_active IP Right Cessation
- 2007-08-28 CA CA2661599A patent/CA2661599C/en not_active Expired - Fee Related
- 2007-08-28 JP JP2009525967A patent/JP5274464B2/ja not_active Expired - Fee Related
- 2007-08-28 AU AU2007291490A patent/AU2007291490A1/en not_active Abandoned
- 2007-08-28 EP EP07801940A patent/EP2069392B1/de not_active Not-in-force
- 2007-08-28 US US12/439,486 patent/US8147843B2/en not_active Expired - Fee Related
- 2007-08-28 WO PCT/EP2007/007517 patent/WO2008025516A2/en not_active Ceased
- 2007-08-28 CA CA2860945A patent/CA2860945C/en not_active Expired - Fee Related
-
2012
- 2012-02-23 US US13/403,826 patent/US8580273B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2069392B1 (de) | 2011-04-13 |
| EP1894940A1 (de) | 2008-03-05 |
| US20120148527A1 (en) | 2012-06-14 |
| CA2661599C (en) | 2015-06-09 |
| US8147843B2 (en) | 2012-04-03 |
| CA2661599A1 (en) | 2008-03-06 |
| WO2008025516A3 (en) | 2008-04-17 |
| US8580273B2 (en) | 2013-11-12 |
| CA2860945C (en) | 2015-12-29 |
| JP5274464B2 (ja) | 2013-08-28 |
| AU2007291490A1 (en) | 2008-03-06 |
| DE602007013920D1 (de) | 2011-05-26 |
| US20110027218A1 (en) | 2011-02-03 |
| EP2069392A2 (de) | 2009-06-17 |
| JP2010501191A (ja) | 2010-01-21 |
| CA2860945A1 (en) | 2008-03-06 |
| WO2008025516A2 (en) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE505481T1 (de) | Fusionsproteine der tnf-superfamilie | |
| WO2009007120A3 (en) | Tnf superfamily collectin fusion proteins | |
| WO2010003766A3 (en) | Multimeric tnf receptors | |
| WO2009068627A3 (en) | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same | |
| WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
| BR0315327A (pt) | Antagonistas de il-15 | |
| DK1767546T3 (da) | Angiogenese-inhiberende kimært protein og dets anvendelse | |
| PH12015500806A1 (en) | Binding molecules to the human ox40 receptor | |
| WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
| NO20053872L (no) | Fusjonskonstruksjoner og anvendelse av disse for fremstilling av antistoffer med okt FC-reseptorbindingsaffinitet og effektorfunksjon. | |
| WO2008066752A8 (en) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| ATE533782T1 (de) | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür | |
| BR0315652A (pt) | Molécula de ácido nucleico isolada, vetor, sistema de vetor-hospedeiro, método de produção de um polipeptìdeo de fusão, ácido nucleico isolado, polipeptìdeo de fusão, e, multìmero | |
| BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
| NO20062886L (no) | IL-23 og dens reseptor, beslektede reagenser og fremgangsmater | |
| WO2008077945A3 (en) | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies | |
| EP3461844A3 (de) | Verbesserte, gegen il-6r gerichtete aminosäuresequenzen und polypeptide damit zur behandlung von erkrankungen und störungen im zusammenhang mit il-6r | |
| AR078111A1 (es) | Anticuerpos del antigeno carcinoembrionario (cea) | |
| DK1888641T3 (da) | Serumalbuminbindende proteiner | |
| WO2008074839A3 (en) | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders | |
| WO2009095489A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| WO2004094651A3 (en) | Novel human polypeptides encoded by polynucleotides | |
| WO2005021578A3 (en) | A novel chimeric polypeptide and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |